A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma

A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunothera...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 28; no. 23; pp. 5010 - 5012
Main Authors Palanki, Rohan, Swingle, Kelsey L, Mitchell, Michael J
Format Journal Article
LanguageEnglish
Published United States 01.12.2022
Subjects
Animals
Cytokines - therapeutic use
Immunity, Innate
Interleukin-2 - administration & dosage
Interleukin-2 - genetics
Mesothelioma - drug therapy
Mesothelioma - pathology
Mesothelioma, Malignant
Mice
Online AccessGet full text

Cover

More Information
Summary:A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy. See related article by Nash et al., p. 5121.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-3
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-22-2626